Abstract
During 2013 (January to December issues) BJCP published, in electronic and no longer in paper-based form, Volumes 75 and 76 comprising: 4 Editors' views, 1 Editors' report, 1 Editors' pick, 1 Viewpoint, 1 Appreciation, 67 Reviews, 6 Systematic reviews, 148 Main papers, 6 Methods in Clinical Pharmacology, 6 Commentaries, 9 Book reviews, 4 Themed sections (Nutraceuticals, Biological Products, Cancer Therapeutics, Novel Therapeutic Approaches to Chronic Kidney Disease), 29 Letters to the Editor, 2 Proceedings/Abstracts with one as a Supplement and a Special Issue ‘Safeguarding Drug Treatment and Health Technology’ which comprised 1 editorial, 1 review and 8 original papers. Most of these data are similar to those in previous years, with the Senior Editorial and Reviews Boards continuing their focus on high quality invited reviews and being underpinned by original and main papers of increasingly high quality. We received (1 January to 31 October 2013) 553 submissions (about 10% fewer compared with the corresponding time period for 2012 – note that we have had increasing numbers of pre-submission enquiries), of which 385 (3% fewer than 2012) were original papers. Of the total submissions, 117 (or 21%) have been accepted and 299 (54%) rejected/withdrawn or relapsed with the remainder pending a decision or awaiting a revision. Of the total number of original papers submitted, 10% have been accepted, 66% rejected and the remaining 24% are pending a decision or awaiting a revision. For the full year in 2012, we accepted 28% of original papers and 76% of review articles. The figures for 2013 to date suggest that the acceptance rate for original papers may be lower, reflecting an increasing number of quality papers that need to be accommodated in the journal. Overall submissions to date came from 63 countries (52 in 2012, 49 in 2011 and 54 in 2010): United Kingdom (85, 16% of total), USA (62, 11%), China (62, 11%), The Netherlands (34, 6.1%), Italy (31, 5.6%), France (28, 5.1%), Germany (26, 4.7%), India (24, 4.3%), Spain (24, 4.3%), Australia (18, 3.3%), Japan (18, 3.3%), Korea (14, 2.5%), Switzerland (14, 2.5%) and 50 other countries with less than 10 submissions each. Compared with 2012, no new country made it into the list of 10 or more submissions whereas Denmark, Sweden and Canada dropped out. Substantial increases were noted from China and Italy. Papers were submitted and handled electronically via the ScholarOne website. Median times (2012 figures in brackets) were as follows: From submission to first decision 25 (24) days; From submission to final decision 28 (23) days; From submission to acceptance 91(95) days. These results show little difference compared with the excellent figures for 2012 in that we can make a final decision within a month. They reflect the outstanding commitment by referees and executive editors in what is a highly competitive market with increased demands on precious time from more journals and more manuscripts. The impact factor pleasingly increased from 2.96 to 3.58. BJCP is now ranked 53rd out of 261 journals in Pharmacology and Pharmacy, a rise of 21 positions from last year. Out of 8471 journals in the impact factor list, the BJCP is ranked 1073rd, a rise of 278 positions and placing it into the top 13% compared with the top 17% last year.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
